

Jane Tchekalarova

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7966366/publications.pdf>

Version: 2024-02-01

82
papers

1,437
citations

304743

22
h-index

414414

32
g-index

82
all docs

82
docs citations

82
times ranked

1507
citing authors

#	ARTICLE	IF	CITATIONS
1	Chronic Piromelatine Treatment Alleviates Anxiety, Depressive Responses and Abnormal Hypothalamicâ€“Pituitaryâ€“Adrenal Axis Activity in Prenatally Stressed Male and Female Rats. <i>Cellular and Molecular Neurobiology</i> , 2022, 42, 2257-2272.	3.3	7
2	The Anticonvulsant Effect of a Novel Indole-Related Compound in the Kainate-Induced Status Epilepticus in Mice: The Role of the Antioxidant and Anti-inflammatory Mechanism. <i>Neurochemical Research</i> , 2022, 47, 327-334.	3.3	3
3	Investigation of the structureâ€“activity relationship in a series of new LVV- and VV-hemorphin-7 analogues designed as potential anticonvulsant agents. <i>Amino Acids</i> , 2022, , 1.	2.7	3
4	Synthesis and characterization of new 5,5â€“dimethyl- and 5,5â€“diphenylhydantoin-conjugated hemorphin derivatives designed as potential anticonvulsant agents. <i>New Journal of Chemistry</i> , 2022, 46, 2198-2217.	2.8	5
5	Impact of Melatonin Deficit on Emotional Status and Oxidative Stress-Induced Changes in Sphingomyelin and Cholesterol Level in Young Adult, Mature, and Aged Rats. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2809.	4.1	4
6	Metabolic footprint in young, middle-aged and elderly rats with melatonin deficit. <i>Physiology and Behavior</i> , 2022, 250, 113786.	2.1	4
7	The anticonvulsant effect of chronic treatment with topiramate after pilocarpine-induced status epilepticus is accompanied by a suppression of comorbid behavioral impairments and robust neuroprotection in limbic regions in rats. <i>Epilepsy and Behavior</i> , 2022, 134, 108802.	1.7	3
8	The role of inflammatory signaling in comorbid depression and epilepsy. , 2021, , 127-137.		0
9	Anticonvulsant Effects of Topiramate and Lacosamide on Pilocarpine-Induced Status Epilepticus in Rats: A Role of Reactive Oxygen Species and Inflammation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2264.	4.1	14
10	Effects of Lacosamide Treatment on Epileptogenesis, Neuronal Damage and Behavioral Comorbidities in a Rat Model of Temporal Lobe Epilepsy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4667.	4.1	9
11	Spectral and electrochemical solvatochromic investigations of newly synthesized peptide-based chemosensor bearing azobenzene side chain bio photoswitch. <i>Dyes and Pigments</i> , 2021, 191, 109348.	3.7	9
12	Reduced neuroinflammation and enhanced neurogenesis following chronic agomelatine treatment in rats undergoing chronic constant light. <i>Neuropharmacology</i> , 2021, 197, 108706.	4.1	11
13	Chronic agomelatine treatment alleviates icvAÎ²-induced anxiety and depressive-like behavior through affecting AÎ² metabolism in the hippocampus in a rat model of Alzheimer's disease. <i>Physiology and Behavior</i> , 2021, 239, 113525.	2.1	5
14	The Role of Melatonin on Behavioral Changes and Concomitant Oxidative Stress in icvAÎ²1-42 Rat Model with Pinealectomy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12763.	4.1	5
15	Agomelatine treatment corrects impaired sleep-wake cycle and sleep architecture and increases MT1 receptor as well as BDNF expression in the hippocampus during the subjective light phase of rats exposed to chronic constant light. <i>Psychopharmacology</i> , 2020, 237, 503-518.	3.1	20
16	Effect of endurance training on diurnal rhythms of superoxide dismutase activity, glutathione and lipid peroxidation in plasma of pinealectomized rats. <i>Neuroscience Letters</i> , 2020, 716, 134637.	2.1	9
17	Structureâ€“activity relationship study on new hemorphin-4 analogues containing steric restricted amino acids moiety for evaluation of their anticonvulsant activity. <i>Amino Acids</i> , 2020, 52, 1375-1390.	2.7	8
18	Evaluation of neurobiological and antioxidant effects of novel melatonin analogs in mice. <i>Saudi Pharmaceutical Journal</i> , 2020, 28, 1566-1579.	2.7	6

#	ARTICLE	IF	CITATIONS
19	Endurance training exerts time-dependent modulation on depressive responses and circadian rhythms of corticosterone and BDNF in the rats with pinealectomy. <i>Brain Research Bulletin</i> , 2020, 162, 40-48.	3.0	5
20	Potential anticonvulsant activity of novel VV-hemorphin-7 analogues containing unnatural amino acids: synthesis and characterization. <i>Amino Acids</i> , 2020, 52, 567-585.	2.7	14
21	Analgesic activity of some aroylhydrazone-based molecular hybrids with antiseizure activity: in vivo and in silico evaluations. <i>Biotechnology and Biotechnological Equipment</i> , 2019, 33, 98-107.	1.3	5
22	The Potential Therapeutic Capacity of Inhibiting the Brain Renin-Angiotensin System in the Treatment of Co-Morbid Conditions in Epilepsy. <i>CNS Drugs</i> , 2019, 33, 1101-1112.	5.9	7
23	Synthesis, characterization and anticonvulsant activity of new series of N-modified analogues of VV-hemorphin-5 with aminophosphonate moiety. <i>Amino Acids</i> , 2019, 51, 1527-1545.	2.7	13
24	Evaluation of the anticonvulsant effect of novel melatonin derivatives in the intravenous pentylenetetrazol seizure test in mice. <i>European Journal of Pharmacology</i> , 2019, 863, 172684.	3.5	7
25	Anticonvulsant evaluation and docking analysis of VV-Hemorphin-5 analogues. <i>Drug Development Research</i> , 2019, 80, 425-437.	2.9	19
26	Antidepressant-like effect of anacardic acid in mice via the L-arginine-nitric oxide-serotonergic system. <i>Phytotherapy Research</i> , 2019, 33, 2126-2138.	5.8	4
27	Discovery of novel indole-based aroylhydrazones as anticonvulsants: Pharmacophore-based design. <i>Bioorganic Chemistry</i> , 2019, 90, 103028.	4.1	28
28	Agomelatine alleviates neuronal loss through BDNF signaling in the post-status epilepticus model induced by kainic acid in rat. <i>Brain Research Bulletin</i> , 2019, 147, 22-35.	3.0	4
29	Synthesis, characterization and anticonvulsant activity of new azobenzene-containing VV-hemorphin-5 bio photoswitch. <i>Amino Acids</i> , 2019, 51, 549-563.	2.7	14
30	Antidepressant agomelatine attenuates behavioral deficits and concomitant pathology observed in streptozotocin-induced model of Alzheimer's disease in male rats. <i>Hormones and Behavior</i> , 2019, 107, 11-19.	2.1	22
31	Chronic agomelatine treatment prevents comorbid depression in the post-status epilepticus model of acquired epilepsy through suppression of inflammatory signaling. <i>Neurobiology of Disease</i> , 2018, 115, 127-144.	4.4	26
32	Losartan suppresses the kainate-induced changes of angiotensin AT 1 receptor expression in a model of comorbid hypertension and epilepsy. <i>Life Sciences</i> , 2018, 193, 40-46.	4.3	15
33	Anxiolytic effect of anacardic acids from cashew (<i>Anacardium occidentale</i>) nut shell in mice. <i>IUBMB Life</i> , 2018, 70, 420-431.	3.4	14
34	Pharmacological characterization of the cannabinoid receptor 2 agonist, Î²-caryophyllene on seizure models in mice. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2018, 57, 22-26.	2.0	29
35	Intracerebroventricular infusion of angiotensin AT2 receptor agonist novokinin aggravates some diabetes-mellitus-induced alterations in Wistar rats. <i>Canadian Journal of Physiology and Pharmacology</i> , 2018, 96, 471-478.	1.4	7
36	Agomelatine treatment corrects symptoms of depression and anxiety by restoring the disrupted melatonin circadian rhythms of rats exposed to chronic constant light. <i>Pharmacology Biochemistry and Behavior</i> , 2018, 171, 1-9.	2.9	45

#	ARTICLE	IF	CITATIONS
37	Anticonvulsant effect of anacardic acid in murine models: Putative role of GABAergic and antioxidant mechanisms. <i>Biomedicine and Pharmacotherapy</i> , 2018, 106, 1686-1695.	5.6	23
38	Abnormal Hippocampal Melatonergic System: A Potential Link between Absence Epilepsy and Depression-Like Behavior in WAG/Rij Rats?. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1973.	4.1	11
39	Effect of Training at Lactate Threshold Intensity on Maximal Time to Exhaustion, Depression and Anxiety Behaviour of Spontaneously Hypertensive Rats after Kainate-Induced Status Epilepticus. <i>Folia Medica</i> , 2017, 59, 91-97.	0.5	6
40	Agomelatine protects against neuronal damage without preventing epileptogenesis in the kainate model of temporal lobe epilepsy. <i>Neurobiology of Disease</i> , 2017, 104, 1-14.	4.4	35
41	In vitro and in silico evaluation of chromene based aroyl hydrazones as anticonvulsant agents. <i>Medicinal Chemistry Research</i> , 2017, 26, 1884-1896.	2.4	9
42	Comparative power spectrum analysis of EEG activity in spontaneously hypertensive and Wistar rats in kainate model of temporal model of epilepsy. <i>Brain Research Bulletin</i> , 2016, 124, 62-75.	3.0	7
43	Recent Developments of Hydrazone/Hydrazone Derivatives and Their Analogs as Anticonvulsant Agents in Animal Models. <i>Drug Development Research</i> , 2016, 77, 379-392.	2.9	55
44	Consequences of long-term treatment with agomelatine on depressive-like behavior and neurobiological abnormalities in pinealectomized rats. <i>Behavioural Brain Research</i> , 2016, 302, 11-28.	2.2	31
45	Long-Term Treatment with Losartan Attenuates Seizure Activity and Neuronal Damage Without Affecting Behavioral Changes in a Model of Co-morbid Hypertension and Epilepsy. <i>Cellular and Molecular Neurobiology</i> , 2016, 36, 927-941.	3.3	34
46	Effects of AT1 receptor antagonism on kainate-induced seizures and concomitant changes in hippocampal extracellular noradrenaline, serotonin, and dopamine levels in Wistar-Kyoto and spontaneously hypertensive rats. <i>Epilepsy and Behavior</i> , 2015, 46, 66-71.	1.7	26
47	Effect of endurance training on seizure susceptibility, behavioral changes and neuronal damage after kainate-induced status epilepticus in spontaneously hypertensive rats. <i>Brain Research</i> , 2015, 1625, 39-53.	2.2	12
48	Long-term intracerebroventricular infusion of angiotensin II after kainate-induced status epilepticus: Effects on epileptogenesis, brain damage, and diurnal behavioral changes. <i>Epilepsy and Behavior</i> , 2015, 51, 1-12.	1.7	9
49	The role of the melatonergic system in epilepsy and comorbid psychiatric disorders. <i>Brain Research Bulletin</i> , 2015, 119, 80-92.	3.0	20
50	Early caffeine exposure: Transient and long-term consequences on brain excitability. <i>Brain Research Bulletin</i> , 2014, 104, 27-35.	3.0	17
51	Antiepileptogenic and neuroprotective effects of losartan in kainate model of temporal lobe epilepsy. <i>Pharmacology Biochemistry and Behavior</i> , 2014, 127, 27-36.	2.9	46
52	Strain-Dependent Effects of Sub-chronically Infused Losartan Against Kainic Acid-Induced Seizures, Oxidative Stress, and Heat Shock Protein 72 Expression. <i>Cellular and Molecular Neurobiology</i> , 2014, 34, 133-142.	3.3	11
53	Treatment with melatonin after status epilepticus attenuates seizure activity and neuronal damage but does not prevent the disturbance in diurnal rhythms and behavioral alterations in spontaneously hypertensive rats in kainate model of temporal lobe epilepsy. <i>Epilepsy and Behavior</i> , 2014, 31, 198-208.	1.7	39
54	Effects of caffeine on cortical epileptic afterdischarges in adult rats are modulated by postnatal treatment. <i>Acta Neurologica Belgica</i> , 2013, 113, 493-500.	1.1	6

#	ARTICLE	IF	CITATIONS
55	Strain-dependent effects of long-term treatment with melatonin on kainic acid-induced status epilepticus, oxidative stress and the expression of heat shock proteins. <i>Pharmacology Biochemistry and Behavior</i> , 2013, 111, 44-50.	2.9	24
56	Prophylactic treatment with melatonin after status epilepticus: Effects on epileptogenesis, neuronal damage, and behavioral changes in a kainate model of temporal lobe epilepsy. <i>Epilepsy and Behavior</i> , 2013, 27, 174-187.	1.7	52
57	Different effects of postnatal caffeine treatment on two pentylenetetrazole-induced seizure models persist into adulthood. <i>Pharmacological Reports</i> , 2013, 65, 847-853.	3.3	3
58	Effect of long-term caffeine administration on depressive-like behavior in rats exposed to chronic unpredictable stress. <i>Behavioural Pharmacology</i> , 2012, 23, 339-347.	1.7	54
59	Diurnal variations in depression-like behavior of Wistar and spontaneously hypertensive rats in the kainate model of temporal lobe epilepsy. <i>Epilepsy and Behavior</i> , 2011, 20, 277-285.	1.7	40
60	The effects of chronic losartan pretreatment on restraint stress-induced changes in motor activity, nociception and pentylenetetrazol generalized seizures in rats. <i>Folia Medica</i> , 2011, 53, 69-73.	0.5	15
61	Transient Changes of Cortical Interhemispheric Responses After Repeated Caffeine Administration in Immature Rats. <i>Physiological Research</i> , 2011, 60, 961-969.	0.9	5
62	Postnatal period of caffeine treatment and time of testing modulate the effect of acute caffeine on cortical epileptic afterdischarges in rats. <i>Brain Research</i> , 2010, 1356, 121-129.	2.2	11
63	Effects of early postnatal caffeine exposure on seizure susceptibility of rats are age- and model-dependent. <i>Epilepsy Research</i> , 2010, 88, 231-238.	1.6	15
64	Dose-dependent effects of caffeine on behavior and thermoregulation in a chronic unpredictable stress model of depression in rats. <i>Behavioural Brain Research</i> , 2010, 209, 205-211.	2.2	47
65	Diurnal rhythms of spontaneous recurrent seizures and behavioral alterations of Wistar and spontaneously hypertensive rats in the kainate model of epilepsy. <i>Epilepsy and Behavior</i> , 2010, 17, 23-32.	1.7	36
66	Postnatal caffeine treatment affects differently two pentylenetetrazol seizure models in rats. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2009, 18, 463-469.	2.0	21
67	Angiotensin II suppresses long-term depression in the lateral amygdala of mice via L-type calcium channels. <i>Neuroscience Letters</i> , 2007, 415, 68-72.	2.1	21
68	Effects of postnatal caffeine exposure on seizure susceptibility in developing rats. <i>Brain Research</i> , 2007, 1150, 32-39.	2.2	21
69	Effect of acute versus chronic theophylline administration on acute restraint stress-induced increase of pentylenetetrazol seizure threshold in mice. <i>Brain Research Bulletin</i> , 2006, 68, 464-468.	3.0	6
70	Biphasic effect of chronic postnatal caffeine treatment on cortical epileptic afterdischarges during ontogeny in rats. <i>Brain Research</i> , 2006, 1082, 43-49.	2.2	13
71	Ang II and Ang III modulate PTZ seizure threshold in non-stressed and stressed mice: Possible involvement of noradrenergic mechanism. <i>Neuropeptides</i> , 2006, 40, 339-348.	2.2	13
72	Up-regulation of adenosine A1 receptor binding in pentylenetetrazol kindling in mice: effects of angiotensin IV. <i>Brain Research</i> , 2005, 1032, 94-103.	2.2	28

#	ARTICLE	IF	CITATIONS
73	Angiotensin peptides modulatory system: how is it implicated in the control of seizure susceptibility?. Life Sciences, 2005, 76, 955-970.	4.3	48
74	Postnatal caffeine exposure: effects on motor skills and locomotor activity during ontogenesis. Behavioural Brain Research, 2005, 160, 99-106.	2.2	41
75	Down-regulation of dopamine D1 and D2 receptors in the basal ganglia of PTZ kindling model of epilepsy: effects of angiotensin IV. Brain Research, 2004, 1024, 159-166.	2.2	15
76	The effects of sarmesin, an Angiotensin II analogue on seizure susceptibility, memory retention and nociception. Regulatory Peptides, 2003, 111, 191-197.	1.9	18
77	Effects of angiotensin III and angiotensin IV on pentylenetetrazol seizure susceptibility (threshold and) Tj ETQq1 1 0.784314 rgBT /Overl 3.0 38	3.0	38
78	Long-term theophylline treatment changes the effects of angiotensin II and adenosinergic agents on the seizure threshold. Brain Research Bulletin, 2000, 52, 13-16.	3.0	10
79	Adenosine-angiotensin II interactions in pentylenetetrazol seizure threshold in mice. Journal of Physiology (Paris), 1999, 93, 191-197.	2.1	22
80	Interaction of angiotensin II and adenosine receptors in pentylenetetrazol-induced kindling in mice. Brain Research, 1998, 779, 259-261.	2.2	15
81	Further evidence for interaction between angiotensin II and dopamine receptors (experiments on) Tj ETQq1 1 0.784314 rgBT /Overl 419. 0.8 6	0.8	6
82	Influence of sarmesin on some dopamine-related types of behaviour. International Journal of Peptide Research and Therapeutics, 1996, 3, 185-190.	0.1	4